Company Directory

Natural product-inspired small molecules for sexual and mental health

Kadence Bio is a clinical-stage biopharma company developing small molecule therapeutics for sexual and mental health. Its lead asset KH-001 is an on-demand oral treatment for premature ejaculation, developed from nature-inspired medicinal chemistry based on kanna plant alkaloids and optimised through standard drug development approaches. KH-001 completed Phase 1 safety studies in 2024 and is progressing to Phase 2 trials. A secondary pipeline targets mood disorders through novel neuropsychiatric compounds.

Clinical-stage CNS drug discovery using human brain genomics

Cerevance is a clinical-stage biotechnology company developing small molecule therapeutics for neurodegenerative and psychiatric disorders. The company uses its proprietary platform to profile gene expression in specific neuronal and glial cell types from a collection of over 16,000 annotated human brain tissue samples, identifying novel drug targets. Combined with machine learning analysis, this approach supports a pipeline of CNS therapeutics targeting conditions including Parkinson's disease, Alzheimer's disease and ALS.

Real-world mental health and dementia data platform for drug development

Akrivia Health is a software company providing a real-world data and AI platform for neuroscience research and drug development. Its dataset of de-identified electronic health records from 6.3 million patients across 20 NHS Trusts covers mental health and dementia conditions, enriched through proprietary natural language processing. Commercial applications include health economics and outcomes research, clinical trial patient recruitment, pharmacovigilance, and drug discovery target identification.

Precision medicine biotech targeting psychiatric and neurological conditions

Monument Therapeutics is a clinical-stage biotechnology company applying precision medicine to CNS drug development. The company uses proprietary digital biomarkers to stratify patients by shared neurobiological profiles, matching them to targeted small molecule treatments. Its pipeline addresses conditions of high unmet need, including cognitive impairment associated with schizophrenia and neuroinflammation. By combining patient stratification with novel reformulations of well-characterised CNS-active compounds, Monument aims to improve clinical trial success rates in psychiatry and neurology.

Synthetic psilocybin therapy for treatment-resistant depression and PTSD

Compass Pathways is a clinical-stage biopharmaceutical company developing synthetic psilocybin-based treatments for mental health conditions. Its lead candidate, COMP360, is a proprietary synthesised psilocybin formulation administered alongside structured psychological support. COMP360 holds FDA Breakthrough Therapy designation and UK ILAP designation for treatment-resistant depression and is currently in two Phase 3 pivotal trials. A separate programme in post-traumatic stress disorder is advancing toward late-stage clinical development following positive Phase 2 data.

Neuroactive therapeutics through genetic engineering of fungi and plants

Empyrean Neuroscience is a biopharma company that uses genetic engineering of fungi and plants to develop small molecule therapeutics for neuropsychiatric and neurologic disorders. Using CRISPR/Cas9 and proprietary transformation technologies, the platform enables precise modulation of neuroactive compound production. Its pipeline targets major depressive disorder, PTSD, substance abuse, and chronic pain, with programmes focused on fungal alkaloids, cannabinoids, and related molecules.

Specialist CNS and psychiatric clinical trial design and delivery organisation

Clerkenwell Health is a London-based specialist contract research organisation providing clinical trial design, regulatory submission, and trial delivery services for CNS, psychiatric, and psychedelic-assisted therapy research. The company operates a purpose-built clinical site network, including an NHS-embedded research unit in Doncaster, and provides specialist patient recruitment and therapist training for mental health and neurological trials. Clients are pharmaceutical and biotechnology companies developing treatments across depression, PTSD, anxiety, dementia, and neurodegeneration.

AI-powered EEG platform for CNS clinical trials

Cumulus Neuroscience is a digital health software company providing an integrated brain monitoring and analytics platform for neuroscience clinical trials. Its platform combines a medical-grade EEG headset with machine learning analytics to generate objective, at-home physiological and cognitive biomarker data. Designed with ten leading pharmaceutical companies, the platform supports drug development across Alzheimer's disease, Parkinson's disease, depression, and schizophrenia.

Digital cognitive assessment and CNS clinical trial software platform

Cambridge Cognition is a software company providing digital cognitive assessment and clinical trial technology for central nervous system drug development. Its validated computerised assessments measures cognitive function across memory, attention, and executive domains, with applications spanning Alzheimer's disease, schizophrenia, and other neurological conditions. Additional products include an AI-driven quality assurance platform for CNS clinical scales, electronic clinical outcome assessments, and a decentralised clinical trial management platform.

Stem cell platform for precision psychiatry and drug discovery

MeOmics Precision Medicine is a biotechnology company developing a precision psychiatry platform that combines genomics, phenomics, and stem cell-based cellular assays to generate biomarkers for severe mental illness. Patient-derived neurons, stimulated via multi-electrode array recording, produce electrophysiological signatures used to stratify patients by biological subtype and predict drug response in vitro. The platform is designed to support pharmaceutical drug discovery for conditions including schizophrenia and bipolar disorder, reducing attrition in clinical development.

Small molecule neuromodulators for neuropsychiatric disorders

Draig Therapeutics is a clinical-stage biotech developing small molecule drugs that modulate the glutamate and GABA neurotransmitter pathways to treat neuropsychiatric disorders. Its lead candidate DT-101 is an AMPA receptor positive allosteric modulator in Phase 2 development for major depressive disorder. The pipeline also includes selective GABAA receptor modulators advancing towards clinical development. Draig's science is founded on research from the Medicines Discovery Institute at Cardiff University.

Precision small molecule drugs for obsessive-compulsive disorder

Serenatis Bio is a preclinical-stage biotech developing small molecule drugs to treat obsessive-compulsive disorder (OCD). Its pipeline of three candidates targets distinct neurological mechanisms, including glutamate, AMPA, and dopamine pathways, with a biomarker-driven approach designed to match patients to treatments by biological subtype. The lead programme, SB001, is an mGluR2/3 modulator developed from research with the University of Cambridge.